Pharmaceutical Executive
Facing patent expiry for one of its top drugs and an overabundance of sales staff due to recent acquisitions, King announced that it would eliminate 760 jobs.
Pharmaceutical Executive-02-05-2009
Advertisement
Advertisement
Trending on PharmExec
1
Mark Cuban Pushes for Generic Drug Fee Waivers, as Cost Plus Drugs Eyes US Manufacturing Expansion
2
Five Steps for Successful CGT Commercialization Through Health Systems Partnerships
3
FDA Approves Breyanzi for Adults with Relapsed or Refractory Marginal Zone Lymphoma
4
Pharmaceutical Executive Daily: FDA Names Tracy Beth Høeg as Acting Director of CDER
5
